Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Q4 2024 Earnings Call Transcript January 28, 2025 Operator: Good afternoon, and welcome to the Alexandria Real Estate ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%.

The company also delayed its break-even timeline from 2026 to 2028. View of Moderna company office entrance exterior with logo sign in Cambridge, Massachusetts, June 14, 2024. Shares fell 19 ...

Moderna Inc. entered the new year on the heels ... deal GSK acquires local cancer biotech in $1.1B deal George Church's lab gets $1.5M to create artificial wombs George Church's lab gets $1.5M ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...